Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xiao-Jun Wu, Yi Zhi, Peng He, Xiao-Zhou Zhou, Ji Zheng, Zhi-Wen Chen & Zhan-Song Zhou. (2016) Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis. OncoTargets and Therapy 9, pages 1535-1543.
Read now
Read now
Mark Bachner & Maria De Santis. (2008) Vinflunine in the treatment of bladder cancer. Therapeutics and Clinical Risk Management 4:6, pages 1243-1253.
Read now
Read now
N. Tsavaris, C. Kosmas, H. Skopelitis, A. Dimitrakopoulos, P. Kopteridis, D. Bougas, K. Stravodimos, D. Mitropoulos, C. Alamanis & A. Giannopoulos. (2005) Methotrexate-Paclitaxel-Epirubicin-Carboplatin (M-TEC) Combination Chemotherapy in Patients with Advanced Bladder Cancer: An Open Label Phase II Study. Journal of Chemotherapy 17:4, pages 444-448.
Read now
Read now
Umberto Basso, Pierfrancesco Bassi & Silvio Monfardini. (2004) Management of muscle-invasive bladder cancer in the elderly. Expert Review of Anticancer Therapy 4:6, pages 1017-1035.
Read now
Read now
Articles from other publishers (24)
Joaquim Bellmunt, Aly-Khan A. Lalani, Sussana Jacobus, Stephanie A. Wankowicz, Laura Polacek, David Y. Takeda, Lauren C. Harshman, Nikhil Wagle, Irene Moreno, Kevin Lundgren, Dominick Bossé, Eliezer M. Van Allen, Toni K. Choueiri & Jonathan E. Rosenberg. (2018) Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer 119:6, pages 707-712.
Crossref
Crossref
Jesus García-Donas, Albert Font, Begoña Pérez-Valderrama, José Antonio Virizuela, Miquel Ángel Climent, Susana Hernando-Polo, José Ángel Arranz, Maria del Mar Llorente, Nuria Lainez, José Carlos Villa-Guzmán, Begoña Mellado, Aránzazu González del Alba, Daniel Castellano, Enrique Gallardo, Urbano Anido, Xavier García del Muro, Montserrat Domènech, Javier Puente, Rafael Morales-Barrera, Jose Luis Pérez-Gracia & Joaquim Bellmunt. (2017) Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. The Lancet Oncology 18:5, pages 672-681.
Crossref
Crossref
Gaetano Facchini, Chiara Della Pepa, Carla Cavaliere, Sabrina C. Cecere, Marilena Di Napoli, Carmine D'Aniello, Anna Crispo, Gelsomina Iovane, Piera Maiolino, Teresa Tramontano, Raffaele Piscitelli, Salvatore Pisconti, Maurizio Montella, Massimiliano Berretta, Domenico Sorrentino, Sisto Perdonà & Sandro Pignata. (2016) From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. Frontiers in Pharmacology 7.
Crossref
Crossref
Spyridon Sideris, Fouad Aoun, Marc Zanaty, Nieves Martinez, Sofia Latifyan, Ahmad Awada & Thierry Gil. (2016) Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Molecular and Clinical Oncology.
Crossref
Crossref
Wei Shen Tan, Benjamin W. Lamb, Heather Payne, Simon Hughes, James S.A. Green, Tim Lane, Jim Adshead, Greg Boustead & Nikhil Vasdev. (2015) Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer 13:3, pages e153-e158.
Crossref
Crossref
Sujata Narayanan, Lauren C. Harshman & Sandy Srinivas. (2015) Second-Line Therapies in Metastatic Urothelial Carcinoma. Hematology/Oncology Clinics of North America 29:2, pages 341-359.
Crossref
Crossref
Amal Halim & Niveen Abotouk. (2013) Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II study. Asia-Pacific Journal of Clinical Oncology 9:1, pages 60-65.
Crossref
Crossref
Holger Gerullis, Thorsten Ecke, Christoph Eimer, Mohamed Wishahi & Thomas Otto. (2011) Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma. Anti-Cancer Drugs 22:1, pages 9-17.
Crossref
Crossref
Maria De Santis & Mark Bachner. 2011. Bladder Tumors:. Bladder Tumors:
409
431
.
Dimitrios Pectasides, Eirini Pectasides, George Papaxoinis, Nikolaos Xiros, Konstantinos Kamposioras, Nikolaos Tountas & Theofanis Economopoulos. (2010) Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors. Urologic Oncology: Seminars and Original Investigations 28:6, pages 617-623.
Crossref
Crossref
Guru Sonpavde, Cora N Sternberg, Jonathan E Rosenberg, Noah M Hahn, Matthew D Galsky & Nicholas J Vogelzang. (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The Lancet Oncology 11:9, pages 861-870.
Crossref
Crossref
M. Retz & J. GschwendM. Retz & J. Gschwend. 2010. Medikamentöse Tumortherapie in der Uroonkologie. Medikamentöse Tumortherapie in der Uroonkologie
3
25
.
Mark Bachner & Maria De Santis. (2009) Second-line therapy in bladder cancer. Current Opinion in Urology 19:5, pages 533-539.
Crossref
Crossref
M. Retz, J.E. Gschwend & J. Lehmann. (2009) Chemotherapie des HarnblasenkarzinomsSystemic chemotherapy for bladder cancer. Der Urologe 48:6, pages 655-662.
Crossref
Crossref
J. Bellmunt, S. Albiol, C. Su?rez & J. Albanell. (2009) Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Critical Reviews in Oncology/Hematology 69:3, pages 211-222.
Crossref
Crossref
Margitta Retz & Jürgen Gschwend. 2009. Medikamentöse Tumortherapie in der Uroonkologie. Medikamentöse Tumortherapie in der Uroonkologie
1
15
.
K S Han, J Y Joung, T S Kim, I G Jeong, H K Seo, J Chung & K H Lee. (2007) Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. British Journal of Cancer 98:1, pages 86-90.
Crossref
Crossref
Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, Bruno Chauvet, Marc Colombel, Jean-Louis Davin, Guy Laurent, Thierry Lebret, Marc Maidenberg, Catherine Mazerolles, Christian Pfister, Morgan Roupret, Catherine Roy, François Rozet, Fabien Saint & Christine Theodore. (2007) . Progrès en Urologie 17:6, pages 1065-1098.
Crossref
Crossref
Joaquim Bellmunt & Santiago Albiol. (2007) Chemotherapy for Metastatic or Unresectable Bladder Cancer. Seminars in Oncology 34:2, pages 135-144.
Crossref
Crossref
José Ma Quintela, Carlos Peinador, Mar誕 J. Moreira, Rosa Toba & Marcos Chas. (2006) A Ready One-pot Preparation for Pteridine and Isoxazolo[3,4-d]pyrimidine Derivatives. HETEROCYCLES 68:5, pages 933.
Crossref
Crossref
Aleem Gangjee, Zhengqu Ye & Sherry F. Queener. (2005)
Synthesis of three carbon atom bridged 2,4-diaminopyrrolo[2,3-
d
]-pyrimidines as nonclassical dihydrofolate reductase inhibitors
. Journal of Heterocyclic Chemistry 42:6, pages 1127-1133.
Crossref
Crossref
Eric Winquist, Malcolm J. Moore, Kim N. Chi, D. Scott Ernst, Hal Hirte, Scott North, Jean Powers, Wendy Walsh, Therese Boucher, Robert Patton & Lesley Seymour. (2005) A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer?. Urologic Oncology: Seminars and Original Investigations 23:3, pages 143-149.
Crossref
Crossref
C. Theodore, L. Geoffrois, J.B. Vermorken, F. Caponigro, W. Fiedler, P. Chollet, A. Ravaud, G.J. Peters, C. de Balincourt, D. Lacombe & P. Fumoleau. (2005) Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. European Journal of Cancer 41:8, pages 1150-1157.
Crossref
Crossref
Cora N Sternberg. (2003) Metastatic Bladder Cancer: Role of Chemotherapy and New Agents. EAU Update Series 1:2, pages 108-117.
Crossref
Crossref